- SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS
-
Described herein are compounds of Formula (I), Formula (I-A), and Formula (I-B), solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing, Further described herein are methods of inhibiting NLRP3 using said compounds, and methods of and compositions useful in treating NLRP3-dependent disorders.
- -
-
Paragraph 0990; 0991
(2021/07/31)
-
- ATG7 INHIBITORS AND THE USES THEREOF
-
Disclosed are chemical entities which are compounds of formula (I) : or a pharmaceutically acceptable salt thereof, wherein R1, R2, and Ra have the values described herein. Chemical entities according to the disclosure can be useful as inhibitors of ATG7. Further provided are pharmaceutical compositions comprising a chemical entity of the disclosure and methods of using the compositions in the treatment of cancer.
- -
-
Paragraph 00353
(2018/05/27)
-
- Synthesis and antianxiety activity of (ω-piperazinylalkoxy)indan derivatives
-
A series of (ω-piperazinylalkoxyl)indan derivatives has been synthesized and screened for potential antianxiety activities. The effect of structural modification of these molecules on activities has been systematically examined. Antianxiety activity was displayed by 5-[3-(4-phenyl-1-piperazinyl)propoxy]indan (2), 5-[3-(4-[4-fluorophenyl)-1-piperazinyl]propoxy]indan (8), 6-fluoro-5-[3-(4-phenyl-1-piperazinyl)propoxy]indan (33), and 6-methyl-5-[3-(4-phenyl-1-piperazinyl)propoxy]indan (42), as determined in antifighting and anti-morphine tests. These derivatives in antianxiety tests were equipotent or more potent than chloridazepoxide with less muscle-relaxant effect. They also showed weak neuroleptic-like action.
- Kikumoto,Tobe,Fukami,Egawa
-
p. 246 - 250
(2007/10/02)
-